Last reviewed · How we verify
Carvedilol CR capsules
At a glance
| Generic name | Carvedilol CR capsules |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease (PHASE1, PHASE2)
- Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives (PHASE1)
- P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy. (PHASE2, PHASE3)
- Coreg CR, Blood Vessel Stiffness and Blood Vessel Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol CR capsules CI brief — competitive landscape report
- Carvedilol CR capsules updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI